About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

"Only after receiving and evaluating this information will we be able to assess the legality and compliance of these specific instruments. The information for investors must be provided in clear, fair, and non-misleading language." The Bank of Lithuania is Robinhood's lead regulator in the European Union after the company received a brokerage license and crypto asset service provider license from the central bank. Robinhood was not immediately available for comment when contacted by CNBC. Lithuania's centra ...

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g. net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get star ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Great Lakes Dredge & Dock (GLDD) - 公司是美国最大的疏浚服务提供商 业务包括维护和加深航道 填海造地以及修复风暴损坏的海岸线 [1] - Zacks评级为1级(强力买入) 过去60天当前年度盈利共识预期增长39.1% [1] - PEG比率为1.05 显著低于行业平均的7.79 [2] - 增长评分为A级 [2] Intercorp Financial Services (IFS) - 公司提供金融产品和服务 Zacks评级为1级 [2] - 过去60天当前年度盈利共识预期增长2.6% [2] - PEG比率为0.36 远低于行业平均的1.51 [2] - 增长评分为B级 [2] European Wax Center (EWCZ) - 个人护理特许经营品牌 提供专业脱毛服务和自有护肤产品 [3] - Zacks评级为1级 过去60天当前年度盈利共识预期增长96.8% [3] - PEG比率为0.51 显著低于行业平均的3.65 [3] - 增长评分为B级 [3]

I am Shubhm Thakkar, an MBA student at the Indian Institute of Management—Indore. I cleared the CFA Level 1 examination that was held in May 2023 and the CFA Level 2 conducted in November 2024. IIM Indore consistently ranks in the Financial Times Top 100 Schools for MBA/ MiM.I have experience publishing on Seeking Alpha as part of my internship at Que Capital, which was a subsidiary of AlmaStreet Capital LLC—an entity that previously published on this platform. At AlmaStreet, I followed a GARP Approach - Gr ...

投资策略 - 投资组合主要包括房地产投资信托基金(REITs)、优先股和高收益债券 [1] - 采用长期基本面分析的投资方法 [1] - 结合多头股票头寸与备兑认购期权和现金担保看跌期权的策略 [1] 研究领域 - 主要关注房地产投资信托基金(REITs)和金融行业 [1] - 偶尔涉及交易所交易基金(ETF)和其他受宏观交易理念驱动的股票 [1] 投资历史 - 2011年开始投资生涯 当时仍处于高中阶段 [1] - 多年来持续保持对市场和经济的高度关注 [1]

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.25%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon.These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVieAbbVie is a pharmaceutical leader with a ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Young Avi asks his grandfather, “Zayde, why do Jews always answer a question with a question?” Zayde chuckles, “Why shouldn’t we? You think goyim have a monopoly on curiosity?” Avi blinks, “But why?” Zayde sighs, “See, now you’re getting it—keep asking, you’ll be a rabbi or a la ...

长期投资视角 - 长期投资者应关注财务表现持续改善、股息稳定增长且增长前景强劲的公司 [1] - Zoetis和Eli Lilly在过去十年中满足上述条件，并有望长期保持，成为优质“永久持有”标的 [2] Zoetis公司分析 - 公司是全球领先的动物健康企业，产品覆盖牲畜、伴侣动物等领域，拥有15款年销售额超1亿美元的产品 [4] - 2014-2023年收入复合年增长率达8%，高于行业平均5% [4] - 近期面临竞争对手新药对主力产品Apoquel（治疗犬过敏性瘙痒）市场份额的挑战，但短期影响有限 [5] - 创新产品如Solensia（2022年获批，治疗猫骨关节炎）和Librela（2023年获批，治疗犬骨关节炎）已推动销售增长 [6] - 长期受益于宠物数量增长、人口增长带来的蛋白质需求提升等趋势 [7][8] - 股息过去十年增长502%，当前股息率1.3%与标普500持平，派息比率31.6%显示未来仍有提升空间 [9] Eli Lilly公司分析 - 公司因减肥药领域成果受关注，过去五年股息翻倍，一季度收入同比激增45%至127亿美元 [10] - 除减肥药外，在免疫学（Taltz）和肿瘤学（Verzenio）等领域拥有重磅药物 [11] - 管线覆盖多治疗领域，新获批产品如阿尔茨海默病药物Kisunla年销售额有望超10亿美元 [12] - 股息率仅0.8%，但派息比率44%及业务基本面强劲，适合长期持有 [13]